Pharmacogenomics in the development and characterization of atheroprotective drugs

Efi Valanti, Alexandros Tsompanidis, Despina Sanoudou

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Atherosclerosis is the main cause of cardiovascular disease (CVD) and can lead to stroke, myocardial infarction, and death. The clinically available atheroprotective drugs aim mainly at reducing the levels of circulating low-density lipoprotein (LDL), increasing high-density lipoprotein (HDL), and attenuating inflammation. However, the cardiovascular risk remains high, along with morbidity, mortality, and incidence of adverse drug events. Pharmacogenomics is increasingly contributing towards the characterization of existing ath­eroprotective drugs, the evaluation of novel ones, and the identification of promising, unexplored thera­peutic targets, at the global molecular pathway level. This chapter presents highlights of pharmacogenomics investigations and discoveries that have contributed towards the elucidation of pharmacological atheropro-tection, while opening the way to new therapeutic approaches.

Original languageEnglish
Pages (from-to)259-300
Number of pages42
JournalMethods in Molecular Biology
Volume1175
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Pharmacogenetics
Drug Evaluation
HDL Lipoproteins
Drug-Related Side Effects and Adverse Reactions
LDL Lipoproteins
Pharmaceutical Preparations
Atherosclerosis
Cardiovascular Diseases
Stroke
Myocardial Infarction
Pharmacology
Inflammation
Morbidity
Mortality
Incidence
Therapeutics

Keywords

  • Adverse effects
  • Atherosclerosis
  • Pharmacogenomics
  • Therapeutic mechanisms
  • Therapeutic targeting

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Pharmacogenomics in the development and characterization of atheroprotective drugs. / Valanti, Efi; Tsompanidis, Alexandros; Sanoudou, Despina.

In: Methods in Molecular Biology, Vol. 1175, 2014, p. 259-300.

Research output: Contribution to journalArticle

Valanti, Efi ; Tsompanidis, Alexandros ; Sanoudou, Despina. / Pharmacogenomics in the development and characterization of atheroprotective drugs. In: Methods in Molecular Biology. 2014 ; Vol. 1175. pp. 259-300.
@article{9c413dad955845748d59a088d4ea0f48,
title = "Pharmacogenomics in the development and characterization of atheroprotective drugs",
abstract = "Atherosclerosis is the main cause of cardiovascular disease (CVD) and can lead to stroke, myocardial infarction, and death. The clinically available atheroprotective drugs aim mainly at reducing the levels of circulating low-density lipoprotein (LDL), increasing high-density lipoprotein (HDL), and attenuating inflammation. However, the cardiovascular risk remains high, along with morbidity, mortality, and incidence of adverse drug events. Pharmacogenomics is increasingly contributing towards the characterization of existing ath­eroprotective drugs, the evaluation of novel ones, and the identification of promising, unexplored thera­peutic targets, at the global molecular pathway level. This chapter presents highlights of pharmacogenomics investigations and discoveries that have contributed towards the elucidation of pharmacological atheropro-tection, while opening the way to new therapeutic approaches.",
keywords = "Adverse effects, Atherosclerosis, Pharmacogenomics, Therapeutic mechanisms, Therapeutic targeting",
author = "Efi Valanti and Alexandros Tsompanidis and Despina Sanoudou",
year = "2014",
doi = "10.1007/978-1-4939-0956-8_11",
language = "English",
volume = "1175",
pages = "259--300",
journal = "Methods in molecular biology (Clifton, N.J.)",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - Pharmacogenomics in the development and characterization of atheroprotective drugs

AU - Valanti, Efi

AU - Tsompanidis, Alexandros

AU - Sanoudou, Despina

PY - 2014

Y1 - 2014

N2 - Atherosclerosis is the main cause of cardiovascular disease (CVD) and can lead to stroke, myocardial infarction, and death. The clinically available atheroprotective drugs aim mainly at reducing the levels of circulating low-density lipoprotein (LDL), increasing high-density lipoprotein (HDL), and attenuating inflammation. However, the cardiovascular risk remains high, along with morbidity, mortality, and incidence of adverse drug events. Pharmacogenomics is increasingly contributing towards the characterization of existing ath­eroprotective drugs, the evaluation of novel ones, and the identification of promising, unexplored thera­peutic targets, at the global molecular pathway level. This chapter presents highlights of pharmacogenomics investigations and discoveries that have contributed towards the elucidation of pharmacological atheropro-tection, while opening the way to new therapeutic approaches.

AB - Atherosclerosis is the main cause of cardiovascular disease (CVD) and can lead to stroke, myocardial infarction, and death. The clinically available atheroprotective drugs aim mainly at reducing the levels of circulating low-density lipoprotein (LDL), increasing high-density lipoprotein (HDL), and attenuating inflammation. However, the cardiovascular risk remains high, along with morbidity, mortality, and incidence of adverse drug events. Pharmacogenomics is increasingly contributing towards the characterization of existing ath­eroprotective drugs, the evaluation of novel ones, and the identification of promising, unexplored thera­peutic targets, at the global molecular pathway level. This chapter presents highlights of pharmacogenomics investigations and discoveries that have contributed towards the elucidation of pharmacological atheropro-tection, while opening the way to new therapeutic approaches.

KW - Adverse effects

KW - Atherosclerosis

KW - Pharmacogenomics

KW - Therapeutic mechanisms

KW - Therapeutic targeting

UR - http://www.scopus.com/inward/record.url?scp=84926610995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926610995&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-0956-8_11

DO - 10.1007/978-1-4939-0956-8_11

M3 - Article

C2 - 25150873

AN - SCOPUS:84926610995

VL - 1175

SP - 259

EP - 300

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

SN - 1064-3745

ER -